Antimicrobial resistance (AMR) is a complex issue of global concern with potentially dramatic health and economic consequences.
The OECD provides countries with the evidence to implement effective and cost-effective One Health policies to tackle AMR, promote effective use of antimicrobials in human and animal health, strengthen infection prevention and control measures, and incentivise research and development in the antibiotic sector.
LATEST EVENT – European Antibiotic Awareness Day 2023
On the European Antibiotic Awareness Day (EAAD) 2023, the OECD released a new Policy Brief presenting key findings of the latest OECD analysis on antimicrobial resistance (AMR) - Embracing a One Health Framework to Fight Antimicrobial Resistance - for the European Union (EU)/European Economic Area (EEA) countries.
Key documents on antimicrobial resistance
G7 WORK ON AMR
The G7 has consistently committed to tackling global health challenges, including the fight against infectious diseases, and positioned itself as a leading partner in reaching health-related Millennium Development Goals, by initiating and supporting many global instruments of response to threats posed by infectious diseases.
In 2022, the German Presidency of the G7 commissioned OECD and WHO a joint briefing paper on addressing the burden of infections and antimicrobial resistance associated with healthcare, with a focus on G7 Countries. Findings in the report assess the level of implementation of infection prevention and control policies both in G7 countries and globally to make a strong economic case for scaling up action.
In 2015, the OECD released a first report to support G7 action in the area of AMR:
G20 WORK ON AMR
Read the note prepared for the G20 by OECD along with WHO, FAO and OIE, on potential strategies to tackle antimicrobial resistance (AMR) and ensure sustainable research and development (R&D) for new antibiotics. The note calls for action based on a coordinated and cross-sectoral approach under the ‘One Health’ framework, highlights the urgent need to address barriers to innovation and suggests policy and governance mechanisms to reactivate the antibiotic R&D pipeline.
In the Hamburg G20 declaration, leaders called for a new R&D Collaboration Hub and committed to further examine practical market incentive options, in collaboration with relevant experts including from the OECD and the WHO.
For more information, please contact firstname.lastname@example.org